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Abstract
Background: Despite the apparent low incidence of cancer metastatic to the thyroid, autopsy and
clinical series suggest it is more common than generally. Although lung, renal, and breast cancer are
probably the most common primary sites, a number of cancers have been reported to metastasize
to the thyroid synchronously with diagnosis of primary tumor or years after apparently curative
treatment.
Case presentation: We report a rare case of a hepatocellular carcinoma metasatic to the
thyroid. The patient presented seven months after original diagnosis and treatment with hepatic
lobectomy with multiple neck lesions producing a mass effect on the trachea and bilateral
lymphadenopathy. Fine-needle aspiration revealed highly anaplastic carcinoma, and
immunohistochemistry confirmed hepatocellular carcinoma. The patient received total
thyroidectomy as palliative therapy because of the presence of multiple recurrent lesions in the
liver.
Conclusion: Clinicians should consider the possibility of metastatic cancer in each patient who
presents with a new thyroid mass, especially those with a history of cancer, however remote. In
cases where cytology or histology is not diagnostic, immunohistochemistry may be definitive in
making the diagnosis.
Background
Although metastatic disease in the thyroid is infrequently
seen, both autopsy and clinical series indicate the prob-
lem is more common than generally thought. Autopsy
series on patients with cancer have yielded incidence rates
ranging from 1.25% to as high as 24%, and some authors
have suggested that the incidence of metastatic disease in
the thyroid may have risen during the twentieth century
[1,2]. Recent reports suggest that the most common pri-
mary sites are the kidney, lung, breast, and gastrointesti-
nal tract [1-7]. However, a wide variety of cancers may
metastasize to the thyroid, including nasopharyngeal car-
cinoma, choriocarcinoma, osteosarcoma [1], leiyomyosa-
rcoma, liposarcoma [5], melanoma [3], and tumors of
neuroendocrine origin [6,8].
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Our clinical experience with a patient whose hepatocellu-
lar carcinoma (HCC) metastasized to the thyroid led to a
review of the literature, where three other cases involving
HCC were identified [9,10]. Discussion of these cases
highlights possible difficulties in evaluating these
patients, ranging from making the diagnosis to evaluating
thyroid disease in the context of the patient's condition in
order to make treatment decisions and determine progno-
sis. Our experience in Asia allows us to see differences in
the clinical profile of thyroid metastasis compared with
that in Western countries; this may be useful to physicians
who see patients from various parts of the world.
Case presentation
A 54-year-old man was admitted for weight loss, upper
abdominal distension with a palpable mass, and epigas-
tric pain for one month. Dull pain had worsened and the
abdominal mass had become increasingly evident for the
preceding week. His history was remarkable for Hepatitis
B infection for more than 20 years. Physical examination
was negative for spider angioma, shifting dullness, jaun-
dice or scleral icterus, hand flapping tremor, or thyroid
mass. Laboratory data were normal: serum aspartate ami-
notransferase, 18 IU/L; alanine aminotransferase, 18 IU/
L; creatinine, 0.8 mg/dL. Abdominal ultrasonography
revealed a mixed echoic mass at level S3–4 (maximum
diameter, 9.8 cm), and the entire liver parenchyma had
heterogeneous echogenicity. Computed tomography (CT)
of the liver revealed multiple foci of heterogeneously
enhanced mass lesions. The largest was roughly 8.9 cm ×
6.7 cm. Serum alpha-fetoprotein was elevated with a level
of 162.4 ng/mL (normal, < 12 ng/ml).
Left hepatic lobectomy was performed two weeks after ini-
tial diagnosis, and histopathologic analysis revealed a
moderately to poorly differentiated HCC. The cut surface
revealed a well-defined, tan-white, firm tumor measuring
8.4 cm × 6.5 cm × 5.5 cm with obvious necrosis. The
tumor directly invaded the liver capsule and was adherent
to fat on the anterior superior surface. The surgical margin
was 1 cm from the tumor and microscopically negative for
tumor cells. Intraoperatively, two well-defined, black
spongy tumors measuring up to 2 cm in diameter were
noted near the main tumor mass. No liver cirrhosis,
cholestasis, or portal vein thrombosis was seen.
Microscopically, the tumor featured cells growing in solid
nests and a pseudoglandular, as well as a focal trabecular
pattern. Individual cells showed marked nuclear pleomor-
phism and prominent nucleoli with abundant eosi-
nophilic granular cytoplasm and frequent mitotic figures.
There was extensive fibrosis and necrosis. Perineural inva-
sion was found near the hilum, but no invasion of blood
or lymphatic vessels was evident. Mucicarmine stain was
negative for mucin in the carcinoma. In scattered areas,
cells were immunochemically positive for cytokeratin
(CK) 7 and negative for CK 20. The two small black and
spongy tumors were typical of cavernous hemangioma.
No liver cirrhosis was noted. After complete pathologic
examination, the patient's pTNM stage according to the
AJCC Cancer Staging Manual (6th  Edition) [11] was
pT1N0M0 (solitary tumor without vascular invasion).
At follow-up two months after surgery, no local recurrence
or metachronous HCC was observed. The patient had a
normal CT and alpha-fetoprotein level had markedly
decreased to 66.5 ng/mL. Four months after surgery,
abdominal CT revealed multiple poorly defined
hypodense lesions (largest about 1 cm) in segments VII
and VIII. Alpha-fetoprotein level was 119.7 ng/mL. Tran-
sarterial embolization therapy was performed for recur-
rent disease. Seven months after surgery alpha-fetoprotein
level was 102.9 ng/mL and recurrent HCC was found.
Transarterial embolization therapy was performed again.
At this time the patient reported new-onset dyspnea and
several neck nodules. Physical examination revealed a
firm, hard left thyroid mass with bilateral lymphadenop-
athy. Ultrasonography revealed multiple nodules in the
left thyroid with heterogeneous echogenicity (Figure 1).
Fine needle aspiration of the largest thyroid nodule was
performed, and cytology revealed poorly differentiated
carcinoma.
Immunohistochemical staining showed that the thyroid
carcinoma was negative for thyroid transcription factor-1
(TTF-1), CK 7, CK 20, and thyroglobulin. Because the car-
cinoma was similar microscopically to the HCC found in
the liver (Figure 2A, B) and positive for alpha-fetoprotein
(Figure 3A, B), a tentative diagnosis of metastatic HCC
with bilateral lymph node involvement was made. Eight
months after the original hepatic lobectomy, the patient
Computed tomography of the neck revealed the left thyroid  tumor (arrow) Figure 1
Computed tomography of the neck revealed the left thyroid 
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underwent total thyroidectomy with bilateral regional
lymph node dissection. Both dysphagia and dyspnea
resolved postoperatively. The patient expired eight
months after the thyroidectomy due to recurrent HCC
complicated by sepsis.
Discussion
Metastatic thyroid cancer may be more common than pri-
mary thyroid malignancy, especially in patients who have
a history of cancer [7]. A variety of presentations, from
neck masses felt by the patient to nodular goiters discov-
ered on physical examination have been reported, as have
lesions revealed on imaging studies [1,2,7,9,12]. Our
patient's presentation with multiple nodules, bilateral
lymphadenopathy, and dysphagia and dyspnea, strongly
suggested advanced local or metastatic cancer. In light of
the patient's recurrent HCC and results of fine needle aspi-
ration of the thyroid lesion, both the surgeon and pathol-
ogist believed it more likely the thyroid mass represented
metastatic HCC than a primary neoplasm. Total thyroid-
ectomy with regional lymph node dissection was per-
formed and pathological examination confirmed the
diagnosis of metastatic HCC. A previous case report of
HCC metastatic to the thyroid indicates that a markedly
different clinical picture can develop with the same pri-
mary neoplasm. In this case, an elderly man had no his-
tory of cancer presented with a single neck mass that
moved with swallowing, which could well have been pri-
mary thyroid cancer [9].
Hematogenous and lymphogenous pathways for metasta-
sis to the thyroid have been suggested [13]. Although one
would consider hematogenous metastasis via a major vein
would be most likely with HCC, it is possible that our
patient had lymphogenous metastasis, with disease
spreading to one or more nodes before spreading to the
thyroid gland itself. Only a series of cases with careful
imaging and pathologic evaluation will determine which
route of metastasis is more common with HCC.
Fine needle aspiration is often used to obtain tissue for
analysis; however, it may be difficult to distinguish pri-
mary from metastatic disease in instances when cells are
highly anaplastic [2]. In the case reported by Masuda et al
[9], fine needle aspirate cytology was not diagnostic, and
a core needle biopsy was obtained. The tissue showed his-
tological architecture resembling a hepatocellular cord
A. Metastatic hepatocellular carcinoma (HCC) in the thyroid  gland (hematoxylin-eosin, 400×) Figure 2
A. Metastatic hepatocellular carcinoma (HCC) in the thyroid 
gland (hematoxylin-eosin, 400×). B. Primary HCC (hematox-
ylin-eosin, 400×).
A. Immunohistochemical staining of the metastatic carcinoma was positive for alpha-fetoprotein (arrow) Figure 3
A. Immunohistochemical staining of the metastatic carcinoma was positive for alpha-fetoprotein (arrow). B. Negative control 
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and positive immunostaining for alpha-fetoprotein. The
primary tumor was discovered on abdominal imaging.
The use of immunohistochemistry has allowed far more
undifferentiated cancers to be correctly identified than
was possible in 1960, when Elliott and Frantz published
their paper on metastatic carcinomas 'masquerading' as
primary thyroid cancers [3]. Because only 20% to 30% of
anaplastic thyroid carcinomas are positive for thyroid
markers such as thyroglobulin, it is important to be aware
of any previous malignancies so appropriate marker stain-
ing can be done [2]. In our case, the thyroid sample was
negative for TTF-1, CK 7, and CK 20, but positive for
alpha-fetoprotein, which is relatively specific for HCC,
although of low sensitivity [14]. A report on use of immu-
nohistochemistry to differentiate several malignancies,
including HCC, that are difficult to distinguish by histol-
ogy and cytology noted that negative stain results for ana-
plastic cytology may not be informative in identifying the
site of origin, and biopsy should be considered [14].
We concur with the recommendation made by several
previous authors that all patients with a history of cancer,
however remote, should be evaluated for possible metas-
tasis when a new thyroid lesion is discovered [2,7]. In our
review of the literature, metastases appeared 15 years
[1,7], 16 years [6], 24 years [2], and 42 years [10] after the
diagnosis of the primary cancer (the last two cases were
renal cell carcinoma and colorectal carcinoma primaries,
respectively). We also agree with Lam and Lo [4], who
compared cases of Chinese and Japanese patients with
those from the West and concluded that differences in pri-
mary sites between Western and Eastern countries proba-
bly reflect incidence rates of cancers in a region rather than
different biological behavior.
Conclusion
Knowledge of an individual patient's personal and family
history, as well as region of origin, may be very useful in
determining what immunostains to perform for patients
with unknown primary tumor and highly anaplastic thy-
roid metastasis. Patients with widely disseminated cancer
have poor prognoses, but patients with a single thyroid
metastasis may have improved quality of life and longer
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